MA41494A - Composés benzoxaborole substitués en position 4 et utilisations associées - Google Patents

Composés benzoxaborole substitués en position 4 et utilisations associées

Info

Publication number
MA41494A
MA41494A MA041494A MA41494A MA41494A MA 41494 A MA41494 A MA 41494A MA 041494 A MA041494 A MA 041494A MA 41494 A MA41494 A MA 41494A MA 41494 A MA41494 A MA 41494A
Authority
MA
Morocco
Prior art keywords
compounds substituted
associated uses
benzoxaborole compounds
ch2ch2ch3
ch2ch3
Prior art date
Application number
MA041494A
Other languages
English (en)
Other versions
MA41494B1 (fr
Inventor
Carlos Alemparte-Gallardo
M R K Alley (Dickon)
David Barros-Aguirre
Ilaria Giordano
Vincent Hernandez
Xianfeng Li
Jacob J Plattner
Original Assignee
Anacor Pharmaceuticals Inc
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55409879&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA41494(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Anacor Pharmaceuticals Inc, Glaxosmithkline Ip No 2 Ltd filed Critical Anacor Pharmaceuticals Inc
Publication of MA41494A publication Critical patent/MA41494A/fr
Publication of MA41494B1 publication Critical patent/MA41494B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/08Antibacterial agents for leprosy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/04Esters of boric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La présente invention concerne des benzoxaboroles substitués dont la structure comprend la formule (iii), dans laquelle r3 est choisi parmi –ch3, –ch2ch3, –ch2=ch2, –ch2ch2ch3, –ch(ch3)2, –ch2ch2=ch2, et un cyclopropyle, r1 et r2 sont chacun indépendamment choisis parmi h, -ch3, -ch2ch3, –ch2ch2ch3, et –ch(ch3)2 ; des compositions contenant de tels composés, leur utilisation en thérapie, y compris leur utilisation comme agents anti-mycobactériens, par exemple dans le traitement d'une infection mycobactérienne chez un mammifère, et des procédés pour la préparation de tels composés.
MA41494A 2015-02-12 2016-02-11 Composés benzoxaborole substitués en position 4 et utilisations associées MA41494B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP15382056 2015-02-12
EP15382054 2015-02-12
EP15382055 2015-02-12
PCT/IB2016/050775 WO2016128948A1 (fr) 2015-02-12 2016-02-12 Composés benzoxaborole substitués en position 4 et utilisations associées

Publications (2)

Publication Number Publication Date
MA41494A true MA41494A (fr) 2017-12-19
MA41494B1 MA41494B1 (fr) 2020-10-28

Family

ID=55409879

Family Applications (2)

Application Number Title Priority Date Filing Date
MA41494A MA41494B1 (fr) 2015-02-12 2016-02-11 Composés benzoxaborole substitués en position 4 et utilisations associées
MA041495A MA41495A (fr) 2015-02-12 2016-02-11 Composés benzoxaborole et leurs utilisations

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA041495A MA41495A (fr) 2015-02-12 2016-02-11 Composés benzoxaborole et leurs utilisations

Country Status (36)

Country Link
US (3) US20180037595A1 (fr)
EP (2) EP3256480A1 (fr)
JP (2) JP6771472B2 (fr)
KR (2) KR20170117158A (fr)
CN (2) CN107531730B (fr)
AU (3) AU2016217508A1 (fr)
BR (2) BR112017017213A2 (fr)
CA (2) CA2976308A1 (fr)
CL (2) CL2017002060A1 (fr)
CO (2) CO2017008816A2 (fr)
CR (2) CR20170372A (fr)
CY (1) CY1123687T1 (fr)
DK (1) DK3256479T3 (fr)
DO (2) DOP2017000188A (fr)
EA (2) EA201791667A1 (fr)
ES (1) ES2821951T3 (fr)
HR (1) HRP20201597T1 (fr)
HU (1) HUE051113T2 (fr)
IL (2) IL253864B (fr)
LT (1) LT3256479T (fr)
MA (2) MA41494B1 (fr)
MX (2) MX379057B (fr)
MY (1) MY194004A (fr)
NZ (1) NZ734379A (fr)
PE (2) PE20171432A1 (fr)
PH (2) PH12017501427A1 (fr)
PL (1) PL3256479T3 (fr)
PT (1) PT3256479T (fr)
RS (1) RS60885B1 (fr)
SG (2) SG11201706510YA (fr)
SI (1) SI3256479T1 (fr)
SM (1) SMT202000565T1 (fr)
TW (2) TWI730953B (fr)
UA (1) UA120527C2 (fr)
WO (2) WO2016128949A1 (fr)
ZA (1) ZA201705456B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4029870A1 (fr) * 2013-08-09 2022-07-20 GlaxoSmithKline Intellectual Property (No.2) Limited Composés de benzoxaborole tricyclique et leurs utilisations
PT3621609T (pt) 2017-05-08 2022-08-24 Glaxosmithkline Ip Dev Ltd Sanfetrinem ou um sal ou um éster do mesmo para a sua utilização no tratamento de infeções micobacterianas
US11834466B2 (en) 2017-11-30 2023-12-05 5Metis, Inc. Benzoxaborole compounds and formulations thereof
BR112021003037A2 (pt) 2018-08-18 2021-05-11 Boragen, Inc. formas sólidas de benzoxaborol substituído e composições do mesmo
CN110441344B (zh) * 2019-06-25 2020-09-29 北京大学 一种基于固体核磁共振技术检测rna结构的方法
CN119233823A (zh) * 2022-06-23 2024-12-31 上海盟科药业股份有限公司 硼化合物治疗非结核分枝杆菌感染的方法和用途及用于治疗相同疾病的药物组合物
CA3239097A1 (fr) 2022-06-23 2023-12-28 Shanghai Micurx Pharmaceutical Co., Ltd. Promedicaments de composes de bore et leur utilisation dans le traitement d'infections bacteriennes
KR20240150582A (ko) 2023-04-08 2024-10-15 김태서 맥세이프 배터리팩을 포함한 아이폰 케이스

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9411587D0 (en) * 1994-06-09 1994-08-03 Zeneca Ltd Compound, composition and use
EP0947498B1 (fr) 1996-12-02 2004-09-15 Chisso Corporation Derives de nitro-alcool optiquement actifs, derives d'amino-alcool optiquement actifs et procede de leur preparation
EP1567464B1 (fr) 2002-12-02 2007-04-18 Solvias AG Hydrogenation catalytique de doubles liaisons carbone-heteroatome
US7767657B2 (en) 2005-02-16 2010-08-03 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
SI3424932T1 (sl) 2005-02-16 2021-08-31 Anacor Pharmaceuticals, Inc. Boronoftalidi za terapevtsko uporabo
WO2006096131A1 (fr) 2005-03-08 2006-09-14 Agency For Science, Technology And Research Catalyseurs chiraux a base de bisoxazoline
TWM325238U (en) * 2006-12-29 2008-01-11 Universal Scient Ind Co Ltd Voltage regulator and voltage regulating system
KR100848491B1 (ko) 2007-01-16 2008-07-28 영진약품공업주식회사 베타아미노기를 갖는 2-싸이아졸리딘 유도체, 이의약학적으로 허용 가능한 염 및 이의 제조 방법
JO3396B1 (ar) 2007-06-20 2019-10-20 Anacor Pharmaceuticals Inc جزيئات صغيرة تحتوي على البورون
CN102256494A (zh) 2008-12-17 2011-11-23 阿纳科制药公司 (s)-3-氨甲基-7-(3-羟基-丙氧基)-3h-苯并[c][1,2]氧杂硼杂环戊-1-醇的多晶型物
WO2011037731A1 (fr) * 2009-09-25 2011-03-31 Anacor Pharmaceuticals, Inc. Petites molécules contenant du bore
EP2555625B1 (fr) * 2010-04-07 2018-11-14 GlaxoSmithKline LLC Procédé de préparation de benzoxaboroles
PT3251678T (pt) * 2010-09-07 2021-11-22 Anacor Pharmaceuticals Inc Derivados de benzoxaborol para tratamento de infeções bacterianas
US8530452B2 (en) 2011-12-22 2013-09-10 Micurx Pharmaceuticals, Inc. Tricyclic boron compounds for antimicrobial therapy
CN102739587B (zh) 2012-06-16 2014-05-21 天地融科技股份有限公司 音频数据传输方法
KR101636431B1 (ko) 2013-07-30 2016-07-05 동아에스티 주식회사 트리사이클릭 벤즈옥사보롤 화합물, 이의 제조방법 및 용도
EP4029870A1 (fr) 2013-08-09 2022-07-20 GlaxoSmithKline Intellectual Property (No.2) Limited Composés de benzoxaborole tricyclique et leurs utilisations

Also Published As

Publication number Publication date
HRP20201597T1 (hr) 2020-12-25
IL253865A0 (en) 2017-10-31
PL3256479T3 (pl) 2021-06-14
JP2018506540A (ja) 2018-03-08
PE20171432A1 (es) 2017-09-26
DK3256479T3 (da) 2020-11-02
US20180037595A1 (en) 2018-02-08
DOP2017000189A (es) 2018-02-15
ES2821951T3 (es) 2021-04-28
EA036516B1 (ru) 2020-11-18
CO2017008809A2 (es) 2017-11-10
MX2017010413A (es) 2018-05-11
UA120527C2 (uk) 2019-12-26
WO2016128948A1 (fr) 2016-08-18
US20210053996A1 (en) 2021-02-25
IL253864B (en) 2021-07-29
EP3256479A1 (fr) 2017-12-20
CL2017002060A1 (es) 2018-03-16
TW201643173A (zh) 2016-12-16
CN107548398A (zh) 2018-01-05
CY1123687T1 (el) 2022-03-24
HUE051113T2 (hu) 2021-01-28
CN107531730A (zh) 2018-01-02
AU2020256369A1 (en) 2020-11-12
CA2976030A1 (fr) 2016-08-18
EA201791671A1 (ru) 2018-02-28
AU2016217508A1 (en) 2017-09-28
BR112017017211A2 (pt) 2018-04-03
CA2976308A1 (fr) 2016-08-18
CL2017002059A1 (es) 2018-03-16
CA2976030C (fr) 2023-09-26
KR20170117158A (ko) 2017-10-20
PH12017501428A1 (en) 2018-01-15
CR20170371A (es) 2018-01-22
US11214582B2 (en) 2022-01-04
AU2016217507A1 (en) 2017-09-28
US10774096B2 (en) 2020-09-15
AU2016217507B2 (en) 2019-03-14
CR20170372A (es) 2017-10-19
EA201791667A1 (ru) 2018-02-28
CN107531730B (zh) 2020-08-07
LT3256479T (lt) 2020-12-28
KR20170117156A (ko) 2017-10-20
EP3256480A1 (fr) 2017-12-20
IL253864A0 (en) 2017-09-28
PH12017501427A1 (en) 2018-01-15
MY194004A (en) 2022-11-07
PE20171348A1 (es) 2017-09-13
MA41494B1 (fr) 2020-10-28
JP2018506538A (ja) 2018-03-08
ZA201705456B (en) 2019-10-30
WO2016128949A1 (fr) 2016-08-18
MX2017010414A (es) 2018-05-11
MA41495A (fr) 2017-12-19
JP6771472B2 (ja) 2020-10-21
SMT202000565T1 (it) 2020-11-10
TW201702250A (zh) 2017-01-16
EP3256479B1 (fr) 2020-07-29
DOP2017000188A (es) 2017-09-15
SG11201706511TA (en) 2017-09-28
BR112017017211B1 (pt) 2023-04-25
NZ734379A (en) 2023-06-30
MX379057B (es) 2025-03-10
PT3256479T (pt) 2020-10-22
SI3256479T1 (sl) 2020-11-30
BR112017017213A2 (pt) 2018-04-03
SG11201706510YA (en) 2017-09-28
CO2017008816A2 (es) 2017-11-10
TWI730953B (zh) 2021-06-21
RS60885B1 (sr) 2020-11-30
US20180044353A1 (en) 2018-02-15

Similar Documents

Publication Publication Date Title
MA41494B1 (fr) Composés benzoxaborole substitués en position 4 et utilisations associées
MA41134A (fr) Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales
MA41625A (fr) Composés de benzazépine dicarboxamide
MA38227A1 (fr) Nouveaux composés bicycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de ?-lactamase
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
MA52486B1 (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA53124B1 (fr) Agents de dégradation sélectifs des récepteurs des oestrogènes
MA38284A1 (fr) Inhibiteurs de la phospholipase associée aux lipoprotéines a2 (lp-pla2) à base de 2,3-dihydro-imidazol[1,2-c]pyrimidin-5(1 h)-one
MA33745B1 (fr) Piperidines substituees qui accroissent l'activite de p53, et utilisation de ces composes
MA46038B1 (fr) Composés de sulfonimidoylpurinone substitués dans la position 7 pour le traitement et la prophylaxie d'infection virale
MA49809A1 (fr) Composés utilisés comme inhibiteurs de kinase
MA45888A1 (fr) Inhibiteurs de tyrosine kinase de bruton
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA40225A (fr) Composés dihydroisoquinolinone substitués
MA34308B1 (fr) Triazolopyridines substituées
MA37762A1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
TN2016000188A1 (fr) Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs.
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
MA34331B1 (fr) Composés pyrazole comme inhibiteurs du récepteur sigma
MA38661A1 (fr) Composés hétéro-aromatiques et leur utilisation en tant que ligands d1 de la dopamine
EP2091328A4 (fr) Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer
MA35748B1 (fr) Fluorométhyl-5,6-dihydro-4h-[1,3]oxazines
WO2019007696A1 (fr) Nouveaux composés et compositions pharmaceutiques de ceux-ci destinés au traitement de la fibrose
TN2009000470A1 (fr) Derives d'azetidine et leur utilisation comme antagonistes de prostaglandine e2
SA522441650B1 (ar) مثبطات فوسفوينوسيتيد 3-كيناز الموضعية